ORTHOCLONE OKT 3 STERILE SOLUTION IV 1MG/ML 1 MG — DIN 02015978
MUROMONAB-CD3 : 1 MG · JANSSEN INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ORTHOCLONE OKT 3 STERILE SOLUTION IV 1MG/ML?
ORTHOCLONE OKT 3 STERILE SOLUTION IV 1MG/ML 1 MG contains MUROMONAB-CD3 : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02015978, held by JANSSEN INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 09-Jul-2007. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Muromonab-Cd3 |
|---|---|
| ATC code | L04AG01 |
| AHFS class | 92:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02015978 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2015978 |
| Brand name | ORTHOCLONE OKT 3 STERILE SOLUTION IV 1MG/ML |
| Generic / active ingredient | MUROMONAB-CD3 : 1 MG |
| Market authorization holder | JANSSEN INC |
| Health Canada schedule | Prescription |
| ATC code | L04AG01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AG |
| Current status | CANCELLED POST MARKET |
| Status date | 09-Jul-2007 |
| Original market date | 1987-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L04AG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Belimumab | BENLYSTA | 4 | 3 | Yes |
| Vedolizumab | ENTYVIO | 3 | 3 | Yes |
| Alemtuzumab | LEMTRADA · MABCAMPATH | 3 | 2 | Yes |
| Ofatumumab | KESIMPTA | 2 | 1 | Yes |
| Inebilizumab | UPLIZNA | 1 | 1 | Yes |
| Natalizumab | TYSABRI | 1 | 1 | Yes |
| Ocrelizumab | OCREVUS | 1 | 1 | Yes |
| Anifrolumab | SAPHNELO | 1 | 1 | Yes |
| Rozanolixizumab | RYSTIGGO | 1 | 1 | Yes |
| Teprotumumab | TEPEZZA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AC | Anakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more | 85 | 75 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.